| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$51.0M | ROE | −36.05% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $305.0M | Trading Days | 1359 |
| 52W High | 2.53 |
| 52W Low | 1.33 |
| % Off High | −8.70% |
| YTD | 12.68% | 1Y | 30.51% |
| 3Y | −4.94% | 5Y | −83.08% |
| Since incept. (ann.) | −42.26% |
| Ann. Volatility (1Y) | 70.04% | Ann. Volatility (3Y) | 99.27% |
| Sharpe (1Y) | 0.73 | Sharpe (3Y) | 0.47 |
| Max Drawdown (1Y) | −26.83% | Max Drawdown (3Y) | −67.98% |
| Beta (3Y, vs SPY) | 0.61 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NMRA | Neumora Therapeutics, Inc. | $307.6M | — |
| AGEN | AGENUS INC | $274.8M | — |
| FATE | FATE THERAPEUTICS INC | $270.4M | — |
| LXEO | Lexeo Therapeutics, Inc. | $344.7M | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $345.3M | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $266.7M | — |
| PALI | PALISADE BIO, INC. | $350.6M | — |
| SABS | SAB Biotherapeutics, Inc. | $263.8M | — |
| ARTV | Artiva Biotherapeutics, Inc. | $260.3M | — |
| EDIT | Editas Medicine, Inc. | $256.5M | — |
| CMPX | Compass Therapeutics, Inc. |
| $367.4M |
| — |
| IPSC | Century Therapeutics, Inc. | $369.7M | — |
